Gossamer Bio Inc is primarily active in the biotechnology industry.

The main competitors of Gossamer Bio Inc in the market are Amgen Inc, Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated.

Gossamer Bio Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics to treat immune-related diseases. Founded in 2015, Gossamer Bio has swiftly emerged as a leader in the biotech industry. With a strong emphasis on innovative research and strategic partnerships, the company aims to address various unmet medical needs. Gossamer Bio's dedicated team of experts strives to enhance patients' lives by advancing the development of novel treatments. With a commitment to scientific excellence, Gossamer Bio Inc remains at the forefront of cutting-edge therapies to improve patient outcomes and revolutionize the field of immunology.

Gossamer Bio Inc has achieved several significant milestones in its journey. Firstly, the company successfully completed its initial public offering (IPO) in February 2019, raising substantial funds to support its operations and growth. Additionally, Gossamer Bio Inc has made significant progress in its clinical pipeline, with the initiation of Phase 2 studies for its lead product candidates in areas such as asthma, chronic rhinosinusitis, and inflammatory bowel disease. These milestones demonstrate the company's commitment to advancing innovative therapies that address unmet medical needs. Gossamer Bio Inc's ongoing efforts and achievements position it as a prominent player in the biopharmaceutical industry.

Gossamer Bio Inc is primarily present in the United States.

Gossamer Bio Inc represents values of innovation, collaboration, and dedication to improving patient outcomes. The company's corporate philosophy revolves around developing and advancing novel therapeutic solutions to address significant unmet medical needs. With a focus on precision medicine and leveraging cutting-edge technology, Gossamer Bio Inc aims to transform the lives of patients by developing innovative treatments for complex diseases. By prioritizing patient-centered approaches and fostering partnerships within the scientific and medical communities, Gossamer Bio Inc strives to make a meaningful impact on healthcare and drive positive change for patients worldwide.

Analysts currently set an average price target of 4,44 USD for the Gossamer Bio stock (median: 2,04 USD), implying +2 425,3 % versus the latest price. The consensus is based on 15 analyst ratings.

Gossamer Bio Analyytikkojen kursstavoitteet 2026

16 analysts currently rate the Gossamer Bio stock: 10 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Gossamer Bio to generate revenue of 36,44 M USD and earnings per share of −0,40 USD.

Gossamer Bio Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Gossamer Bio share trades at 0,15 EUR (0,18 USD).

The Gossamer Bio share (GOSS) is listed on 4 stock exchanges, including: NASDAQ (GOSS), Frankfurt (4GB.F), München (4GB.MU), Düsseldorf (4GB.DU).

Gossamer Bio Inc is an American biotechnology company that is dedicated to the discovery and development of new therapeutics for specific diseases. The company was founded in 2018 by an experienced team of executives and experts in the biotechnology industry. Gossamer Bio is headquartered in San Diego, California and currently employs over 100 employees. The business model of Gossamer Bio can be divided into three main areas: research and development, clinical trials, and marketing. The research and development division focuses on identifying new drug candidates for diseases such as respiratory diseases, inflammatory diseases, oncology, and infectious diseases. The company utilizes state-of-the-art technologies and platforms to identify and optimize promising candidates before testing them in clinical trials. Clinical trials play a crucial role in evaluating the efficacy and safety of drug candidates. Gossamer Bio conducts carefully planned studies to achieve scientific validation of the therapeutics. The company also utilizes a network of leading clinical facilities and research centers to conduct studies and collect data. This helps the company evaluate the efficacy and safety of the therapeutics and submit the best recommendation for drug approval to regulatory authorities. Once the clinical trials are completed and the therapeutics are approved, the company moves into the marketing phase. Gossamer Bio offers its therapeutics directly to patients and healthcare professionals through distribution and marketing channels. The company also utilizes partnerships and licensing agreements to enhance access to various markets and regions. This helps the company minimize distribution costs and maximize the reach of its therapeutics. Gossamer Bio already has several promising drug candidates in its pipeline, including GB001, GB002, GB004, and GB1275. Most of them are targeted towards respiratory diseases such as asthma, chronic lung disease, and idiopathic pulmonary fibrosis. GB001 is an inhaled breast cancer medication, while GB1275 targets various solid tumors including pancreatic cancer. Overall, Gossamer Bio has a strong business model that focuses on research and development, clinical trials, and marketing. As an innovative biotechnology company, they are committed to developing groundbreaking therapeutics that can benefit patients worldwide. Through strategic partnerships and telemedicine models, Gossamer Bio is working to improve healthcare and insurance to ensure that everyone in the world has access to top-quality therapeutics to improve their health.

odotettu liikevaihto Gossamer Bio on 36,44 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Gossamer Bio on −90,49 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Gossamer Bio:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,44. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Gossamer Bio-osakkeen arvostusta.

Gossamer Bio:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,09. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Gossamer Bio-osakkeen arvostuskennuslukuna.

Gossamer Bio:n Eulpool-laatuscore on 3/10.

Gossamer Bio:n ISIN on US38341P1021. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Gossamer Bio:n WKN on A2PCBS. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Gossamer Bio:n ticker on GOSS. Tämä pörssinoteeraus käytetään Gossamer Bio-osakkeiden kauppaan pörssissä.

Gossamer Bio maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Gossamer Bio kuuluu sektoriin 'Terveydenhuolto'.

Gossamer Bio:n osingot jaetaan valuutassa USD.